health Long-term benefits of amivantamab continue in post-platinum NSCLC [ad_1] Long-term data from the CHRYSALIS trial (NCT02609776) continued to demonstrate the clinical benefit of amivantamabvmjw (Rybrevant), according… bynewsdeskMay 30, 2023
